Success Metrics

Active Trials
9(90%)

Phase Distribution

Ph phase_3
3
30%
Ph phase_2
6
60%

Phase Distribution

0

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

10

all time

Status Distribution
Active(10)

Detailed Status

Active, not recruiting5
Recruiting4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
9
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 26 (66.7%)
Phase 33 (33.3%)

Trials by Status

not_yet_recruiting110%
recruiting440%
active_not_recruiting550%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT07645287Phase 2

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

Recruiting
NCT07683000Phase 3

Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Recruiting
NCT07473778

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Recruiting
NCT07682961Phase 3

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Recruiting
NCT07708727Phase 2

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

Not Yet Recruiting
NCT07047716Phase 3

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

Active Not Recruiting
NCT06513312Phase 2

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Active Not Recruiting
NCT05729568Phase 2

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Active Not Recruiting
NCT06101342Phase 2

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Active Not Recruiting
NCT06101329Phase 2

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Active Not Recruiting

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10